DURHAM – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has made a leadership change.
The company announced that, effective September 17, Dr. Vicente Anido, PhD. no longer served as the publicly-traded company’s chairman and CEO or as a director of the company.
Aerie noted in a statement that this move was “consistent with the succession plan in place.”
The company stated that its board of directors has now appointed Benjamin F. McGraw, III, Pharm.D. as the interim executive chairman of the board of directors and that it has begun a search for a new CEO.
Aerie also said it would separate the roles of chairman and CEO moving forward.
The firm focuses on treatment of patients with glaucoma and other eye diseases.
Anido had served as the company’s chief executive and chairman since 2013, according to a LinkedIn profile.
The company’s stock price is down nearly 25% over the last five days of trading, and 20% in the prior month, according to market data from Nasdaq.
